David M. Langenau

David M. Langenau

Auto-generated profile, based on publicly available information

David M. Langenau

Massachusetts General Hospital - Charlestown Navy Yard (CNY) Campus, Charlestown, MA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
EPE. Elizabeth Patton
E. Elizabeth Patton
LZLeonard I. Zon
Leonard I. Zon
DLDavid M. Langenau
David M. Langenau

1 June 2019 in Cell
Verified
Journal Article
Closed access
CYChuan Yan
Chuan Yan
DBDalton C. Brunson
Dalton C. Brunson
QTQin Tang
Qin Tang
DDDaniel Do
Daniel Do
NINicolae A. Iftimia
Nicolae A. Iftimia
DLDavid M. Langenau
David M. Langenau

6 September 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QTQin Tang
Qin Tang
SISowmya Iyer
Sowmya Iyer
RLRiadh Lobbardi
Riadh Lobbardi
JMJohn C. Moore
John C. Moore
HCHuidong Chen
Huidong Chen
DLDavid M. Langenau
David M. Langenau
Recent advances in single-cell, transcriptomic profiling have provided unprecedented access to investigate cell heterogeneity during tissue and organ development. In this study, we used massively parallel, single-cell RNA sequencing to define cell heterogeneity within the zebrafish kidney marrow, constructing a comprehensive molecular atlas of definitive hematopoiesis and functionally distinct renal cells found in adult zebrafish. Because our method analyzed blood and kidney cells in an unbiased manner, our approach was useful in characterizing immune-cell deficiencies within DNA–protein kinase catalytic subunit (prkdc), interleukin-2 receptor γ a (il2rga), and double-homozygous–mutant fish, identifying blood cell losses in T, B, and natural killer cells within specific genetic mutants. Our analysis also uncovered novel cell types, including two classes of natural killer immune cells, classically defined and erythroid-primed hematopoietic stem and progenitor cells, mucin-secreting kidney cells, and kidney stem/progenitor cells. In total, our work provides the first, comprehensive, single-cell, transcriptomic analysis of kidney and marrow cells in the adult zebrafish.

6 April 2020 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MFMaurizio Fazio
Maurizio Fazio
JAJulien Ablain
Julien Ablain
YCYan Chuan
Yan Chuan
DLDavid M. Langenau
David M. Langenau
LZLeonard I. Zon
Leonard I. Zon

24 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FMFinola E. Moore
Finola E. Moore
DRDeepak Reyon
Deepak Reyon
JSJeffry D. Sander
Jeffry D. Sander
SMSarah A. Martinez
Sarah A. Martinez
Jessica BlackburnJessica Blackburn
Jessica Blackburn
DLDavid M. Langenau
David M. Langenau
Zinc Finger Nucleases (ZFNs) made by Context-Dependent Assembly (CoDA) and Transcription Activator-Like Effector Nucleases (TALENs) provide robust and user-friendly technologies for efficiently inactivating genes in zebrafish. These designer nucleases bind to and cleave DNA at particular target sites, inducing error-prone repair that can result in insertion or deletion mutations. Here, we assess the relative efficiencies of these technologies for inducing somatic DNA mutations in mosaic zebrafish. We find that TALENs exhibited a higher success rate for obtaining active nucleases capable of inducing mutations than compared with CoDA ZFNs. For example, all six TALENs tested induced DNA mutations at genomic target sites while only a subset of CoDA ZFNs exhibited detectable rates of mutagenesis. TALENs also exhibited higher mutation rates than CoDA ZFNs that had not been pre-screened using a bacterial two-hybrid assay, with DNA mutation rates ranging from 20%–76.8% compared to 1.1%–3.3%. Furthermore, the broader targeting range of TALENs enabled us to induce mutations at the methionine translation start site, sequences that were not targetable using the CoDA ZFN platform. TALENs exhibited similar toxicity to CoDA ZFNs, with >50% of injected animals surviving to 3 days of life. Taken together, our results suggest that TALEN technology provides a robust alternative to CoDA ZFNs for inducing targeted gene-inactivation in zebrafish, making it a preferred technology for creating targeted knockout mutants in zebrafish.

24 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ECEleanor Y. Chen
Eleanor Y. Chen
MDMichael T. DeRan
Michael T. DeRan
MIMyron S. Ignatius
Myron S. Ignatius
KGKathryn Brooke Grandinetti
Kathryn Brooke Grandinetti
RCRyan Clagg
Ryan Clagg
DLDavid M. Langenau
David M. Langenau
Significance: Embryonal rhabdomyosarcoma (ERMS) is a cancer of skeletal muscle and is one of the most common pediatric cancers of soft tissue. There is no effective treatment for patients with relapsed ERMS, with less than 50% surviving the disease. The self-renewing and molecularly defined tumor propagating cells (TPCs) drive continued tumor growth and relapse. Yet to date, drugs targeting ERMS self-renewal and differentiation of TPCs have not been identified. Our study describes a large-scale chemical screen to identify targetable pathways essential for modulating self-renewal and differentiation of ERMS and demonstrates the feasibility of inducing differentiation of TPCs in ERMS by small molecules.